The FDA has removed the risk evaluation and mitigation strategies (REMS) program requirement for Tryvio (aprocitentan).
Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for prostate cancer ...
The FDA is stepping up its oversight of infant formula, including increased testing for heavy metals and other contaminants.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results